Enclosed herewith is the Press Release.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Supriya Lifescience reported strong Q4 FY26 results with revenue surging 50.2% YoY to Rs 276.53 crore, driven by the anesthetic segment contributing 54% of total revenues. PAT grew 47.4% YoY to Rs 74.23 crore in Q4. For the full year FY26, revenue increased 18.9% to Rs 827.87 crore and PAT rose 11.3% to Rs 209.12 crore. EBITDA margins compressed slightly, with FY26 margin at 35.5% versus 37.4% in FY25. The company expanded capacity utilization to 74% from 70%, commissioned five finished dosage lines at its Ambernath facility, and commercialized its Liquid Anesthetic product. Europe remains the largest market at 40% of FY26 revenues.
Strong top-line and bottom-line growth demonstrates healthy demand in regulated markets, though margin compression warrants monitoring. The diversification into formulations and new therapeutic segments like cardiovascular and ADHD positions the company for sustained growth.